Monitor Halozyme's announcement regarding an appeal to the Federal Circuit and the status of the related district court litigation with Merck. The outcome of this and other related PGR proceedings could materially affect Halozyme's ENHANZE royalty stream.
Price Chart
Executive Summary
The PTAB issued a Final Written Decision in PGR2025-00030, finding all challenged claims (1, 2, and 6–30) of Halozyme's U.S. Patent 12,054,758, covering modified PH20 hyaluronidase polypeptides, unpatentable on written description, enablement, and obviousness grounds. This is a significant loss for Halozyme as the patent is central to its drug delivery technology platform and is involved in a related district court litigation with Merck. The decision may impact Halozyme's ability to enforce this patent against Merck and potentially other competitors.
PTAB Trial Details
Key Facts
- Final Written Decision in PGR2025-00030, finding claims 1, 2, and 6–30 of U.S. Patent 12,054,758 unpatentable.
- Patent covers modified PH20 hyaluronidase polypeptides, a key component of Halozyme's ENHANZE drug delivery technology.
- Petitioner is Merck Sharp & Dohme LLC; the patent is involved in a related civil action (Halozyme, Inc. v. Merck Sharp & Dohme LLC, 2:25-cv-03179 D.N.J.).
- The Board found all challenged claims unpatentable on written description, enablement, and obviousness grounds.
- The decision is a final written decision, subject to appeal to the Federal Circuit.
Financial Impact
The decision cancels a patent central to Halozyme's ENHANZE platform, which underpins its partnered drug delivery revenue. The financial impact is material but not quantified in the decision.
Risk Factors
- Loss of patent protection for key PH20 polypeptide variants could reduce Halozyme's ability to enforce its ENHANZE technology against competitors.
- Multiple related PGR proceedings against other Halozyme patents remain pending, creating cumulative risk to the patent portfolio.
- Merck may seek to invalidate additional Halozyme patents, further weakening Halozyme's intellectual property position.
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2025-00030-fwd-HALO |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | Press Release | $124.54 $125.63 | ▲ +0.88% | ▲ +1.40% | $125.63 (+0.88%) |
Oct 20, 2026 5d ago | Institutional Cluster | $124.83 $124.54 | ▼ −0.23% | ▲ +0.95% | $125.63 (+0.64%) |
Oct 15, 2026 11d ago | PTAB Trial | $121.84 $122.50 | ▼ −0.54% | ▼ −0.12% | $125.63 (−3.11%) |
Oct 15, 2026 11d ago | PTAB Trial | $121.84 $122.50 | ▼ −0.54% | ▼ −0.12% | $125.63 (−3.11%) |
Sep 18, 2026 5w ago | 8-K | $112.45 $111.45 | ▼ −0.89% | ▼ −2.44% | $125.63 (+11.72%) |
Sep 17, 2026 5w ago | Insider Cluster | $112.45 $111.45 | ▼ −0.89% | ▼ −2.44% | $125.63 (+11.72%) |
Aug 19, 2026 9w ago | Insider Cluster | $106.12 $108.17 | ▲ +1.93% | ▲ +1.52% | $125.63 (+18.38%) |
Jul 9, 2026 15w ago | Insider Cluster | $76.20 $76.11 | ▼ −0.12% | ▲ +0.65% | $125.63 (+64.87%) |
Jul 2, 2026 16w ago | Insider Cluster | $80.78 $81.57 | ▲ +0.98% | ▲ +1.45% | $125.63 (+55.52%) |
Jun 3, 2026 20w ago | Insider Cluster | $71.60 $71.53 | ▼ −0.10% | ▲ +2.50% | $125.63 (+75.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers